CoChat

Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Accumulating evidence points to an important role for the gut microbiome in anti-tumor immunity. Here, we show that altered intestinal microbiota contributes to anti-tumor immunity, limiting tumor expansion. Mice lacking the ubiquitin ligase RNF5 exhibit attenuated activation of the unfolded protein response (UPR) components, which coincides with increased expression of inflammasome components, recruitment and activation of dendritic cells and reduced expression of antimicrobial peptides in intestinal epithelial cells. Reduced UPR expression is also seen in murine and human melanoma tumor specimens that responded to immune checkpoint therapy. Co-housing of Rnf5 −/− and WT mice abolishes the anti-tumor immunity and tumor inhibition phenotype, whereas transfer of 11 bacterial strains, including B. rodentium , enriched in Rnf5 −/− mice, establishes anti-tumor immunity and restricts melanoma growth in germ-free WT mice. Altered UPR signaling, exemplified in Rnf5 −/− mice, coincides with altered gut microbiota composition and anti-tumor immunity to control melanoma growth.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09525-y

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Enhanced antitumor immune responses in Rnf5−/− mice. a Growth of YUMM1.5 (BrafV600E:PTEN−/−:Cdkn2a−/−) melanoma cells after subcutaneous injection of 106 cells into WT or Rnf5−/− mice (n = 5). b Quantification of tumor-infiltrating effector (CD44hi) CD4+ and CD8+ T cells and total CD45+ cells on day 24 after tumor injection (n = 5). c Frequencies of tumor-infiltrating TNF-α-, IFN-γ-, and IL-2-producing CD4+ and CD8+ T cells on day 24 after tumor inoculation (n = 5). d Quantification of tumor-infiltrating total DCs, pDCs, mDCs, and CD8α+ DCs on day 24 after tumor inoculation (n = 5). e Expression (mean fluorescence intensity, MFI) of MHC class II, CD40, CD80, and CD86 on tumor-infiltrating DCs (CD45+ CD11c+) on day 24 after tumor inoculation (n = 5). f Quantification of OT-I CD8+ T cells in tumor-draining lymph nodes (TdLN) and non-draining lymph nodes (ndLN) of CD45.1+ WT and Rnf5−/− mice injected with B16-OVA melanoma cells (WT, n = 6; Rnf5−/−, n = 5). g, h Growth of YUMM1.5 melanoma cells in mice injected i.p. with control IgG and anti-CD4 (g) or control IgG and anti-CD8 (h) depleting antibodies on days 0, 3, 6, 11, 16 (n = 9). FACS analysis revealed >90% depletion of blood CD4+ and CD8+ T cells on day 7 after tumor inoculation. i, Growth of YUMM1.5 melanoma cells in lethally irradiated bone marrow-reconstituted WT or Rnf5−/− mice (arrow indicates bone marrow donor → recipient; n = 7). Data are representative of three independent experiments (a–e), two independent experiments (f, i) and one experiment (g, h) ≥5 mice per group. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-way ANOVA with Sidak’s correction (a, g–i) or by two-tailed t-test or Mann–Whitney U test (b–f)
Fig. 1 Enhanced antitumor immune responses in Rnf5−/− mice. a Growth of YUMM1.5 (BrafV600E:PTEN−/−:Cdkn2a−/−) melanoma cells after subcutaneous injection of 106 cells into WT or Rnf5−/− mice (n = 5). b Quantification of tumor-infiltrating effector (CD44hi) CD4+ and CD8+ T cells and total CD45+ cells on day 24 after tumor injection (n = 5). c Frequencies of tumor-infiltrating TNF-α-, IFN-γ-, and IL-2-producing CD4+ and CD8+ T cells on day 24 after tumor inoculation (n = 5). d Quantification of tumor-infiltrating total DCs, pDCs, mDCs, and CD8α+ DCs on day 24 after tumor inoculation (n = 5). e Expression (mean fluorescence intensity, MFI) of MHC class II, CD40, CD80, and CD86 on tumor-infiltrating DCs (CD45+ CD11c+) on day 24 after tumor inoculation (n = 5). f Quantification of OT-I CD8+ T cells in tumor-draining lymph nodes (TdLN) and non-draining lymph nodes (ndLN) of CD45.1+ WT and Rnf5−/− mice injected with B16-OVA melanoma cells (WT, n = 6; Rnf5−/−, n = 5). g, h Growth of YUMM1.5 melanoma cells in mice injected i.p. with control IgG and anti-CD4 (g) or control IgG and anti-CD8 (h) depleting antibodies on days 0, 3, 6, 11, 16 (n = 9). FACS analysis revealed >90% depletion of blood CD4+ and CD8+ T cells on day 7 after tumor inoculation. i, Growth of YUMM1.5 melanoma cells in lethally irradiated bone marrow-reconstituted WT or Rnf5−/− mice (arrow indicates bone marrow donor → recipient; n = 7). Data are representative of three independent experiments (a–e), two independent experiments (f, i) and one experiment (g, h) ≥5 mice per group. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-way ANOVA with Sidak’s correction (a, g–i) or by two-tailed t-test or Mann–Whitney U test (b–f)CC BY · PubMed Central
Fig. 2 Enhanced inflammasome and pathogen receptor signaling in Rnf5−/− mice. a NanoString analysis of PanCancer Immune Profiling genes in tumors from WT and Rnf5−/− mice. The heatmap shows 47 genes with >1.2-fold (P < 0.05) differences in expression between YUMM1.5 tumors from the two genotypes (n = 5) at 10 days after injection. b Growth of B16F10 melanoma cells after subcutaneous injection of 106 cells into WT, Rnf5−/−, MyD88−/− and MyD88−/−Rnf5−/− mice (WT, Rnf5−/−, n = 6; MyD88−/−, n = 5; MyD88−/− Rnf5−/−, n = 8). c qRT-PCR analysis of pathogen receptor mRNA levels in IECs from tumor-bearing WT or Rnf5−/− mice (n = 4). d qRT-PCR analysis of cytokine and chemokine mRNA levels in IECs isolated from the small intestines of tumor-bearing WT or Rnf5−/− mice (n = 4). Data are representative of three independent experiments (c, d), two independent experiments (b) or one experiment (a) ≥5 mice per group. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-tailed t test or Mann–Whitney U test (c, d) or two-way ANOVA with Sidak’s correction (b)
Fig. 2 Enhanced inflammasome and pathogen receptor signaling in Rnf5−/− mice. a NanoString analysis of PanCancer Immune Profiling genes in tumors from WT and Rnf5−/− mice. The heatmap shows 47 genes with >1.2-fold (P < 0.05) differences in expression between YUMM1.5 tumors from the two genotypes (n = 5) at 10 days after injection. b Growth of B16F10 melanoma cells after subcutaneous injection of 106 cells into WT, Rnf5−/−, MyD88−/− and MyD88−/−Rnf5−/− mice (WT, Rnf5−/−, n = 6; MyD88−/−, n = 5; MyD88−/− Rnf5−/−, n = 8). c qRT-PCR analysis of pathogen receptor mRNA levels in IECs from tumor-bearing WT or Rnf5−/− mice (n = 4). d qRT-PCR analysis of cytokine and chemokine mRNA levels in IECs isolated from the small intestines of tumor-bearing WT or Rnf5−/− mice (n = 4). Data are representative of three independent experiments (c, d), two independent experiments (b) or one experiment (a) ≥5 mice per group. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-tailed t test or Mann–Whitney U test (c, d) or two-way ANOVA with Sidak’s correction (b)CC BY · PubMed Central
Fig. 3 Gut microbiota control melanoma growth. a Principal component analysis (PCA) of all taxa enumerated in Rnf5−/− and WT fecal microbiota samples taken before (day 0) and 24 days after injection of YUMM1.5 tumor cells (n = 30). b Elimination of tumor growth suppression in Rnf5−/− mice by treatment with an antibiotic cocktail administered for 2 weeks prior to tumor cell injection (n = 5). c PCA of all taxa showing convergence of gut microbiota in WT and Rnf5−/− mice after co-housing (WT alone, n = 14; Rnf5−/− alone, n = 15; WT mixed, Rnf5−/− mixed, n = 5). d Growth of YUMM1.5 melanoma cells in WT or Rnf5−/− mice housed alone or co-housed (mixed) for 4 weeks prior to tumor inoculation (alone, n = 15; mixed, n = 16). e Quantification of effector (CD44hi) CD4+ and CD8+ T cells, total CD45+ cells, and frequencies of IFN-γ + TNF-α-producing CD4+ and CD8+ T cells in tumors from WT or Rnf5−/− mice housed alone or co-housed for 4 weeks prior to tumor inoculation (n = 10). f Quantification of tumor-infiltrating total DCs, pDCs, and mDCs in WT or Rnf5−/− mice housed alone or co-housed for 4 weeks prior to tumor inoculation (n = 10). g A cladogram representation of taxa enriched in Rnf5−/− mice (red) microbiota and taxa enriched in WT mice (green) microbiota (n = 30). The background color indicates phylum; names of phyla are indicated. Data are representative of two independent experiments ≥5 mice per group. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by one-way ANOVA with Tukey’s (e, f) or two way ANOVA with Sidak’s (b, d) correction for multiple comparisons
Fig. 3 Gut microbiota control melanoma growth. a Principal component analysis (PCA) of all taxa enumerated in Rnf5−/− and WT fecal microbiota samples taken before (day 0) and 24 days after injection of YUMM1.5 tumor cells (n = 30). b Elimination of tumor growth suppression in Rnf5−/− mice by treatment with an antibiotic cocktail administered for 2 weeks prior to tumor cell injection (n = 5). c PCA of all taxa showing convergence of gut microbiota in WT and Rnf5−/− mice after co-housing (WT alone, n = 14; Rnf5−/− alone, n = 15; WT mixed, Rnf5−/− mixed, n = 5). d Growth of YUMM1.5 melanoma cells in WT or Rnf5−/− mice housed alone or co-housed (mixed) for 4 weeks prior to tumor inoculation (alone, n = 15; mixed, n = 16). e Quantification of effector (CD44hi) CD4+ and CD8+ T cells, total CD45+ cells, and frequencies of IFN-γ + TNF-α-producing CD4+ and CD8+ T cells in tumors from WT or Rnf5−/− mice housed alone or co-housed for 4 weeks prior to tumor inoculation (n = 10). f Quantification of tumor-infiltrating total DCs, pDCs, and mDCs in WT or Rnf5−/− mice housed alone or co-housed for 4 weeks prior to tumor inoculation (n = 10). g A cladogram representation of taxa enriched in Rnf5−/− mice (red) microbiota and taxa enriched in WT mice (green) microbiota (n = 30). The background color indicates phylum; names of phyla are indicated. Data are representative of two independent experiments ≥5 mice per group. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by one-way ANOVA with Tukey’s (e, f) or two way ANOVA with Sidak’s (b, d) correction for multiple comparisonsCC BY · PubMed Central
Fig. 4 Oral administration of select bacterial strains enriched in Rnf5−/− mice to gnotobiotic mice enhances antitumor immune response. a YUMM1.5 tumor growth in germ-free (GF) mice undergoing oral gavage with WT or Rnf5−/− cecal contents 2 weeks prior to tumor implantation (n = 10). b Quantification of tumor-infiltrating CD45+ cells, effector (CD44hi) CD4+ and CD8+ T cells, total CD45+ cells, and frequencies of IFN-γ+TNF-α+-producing CD4+ and CD8+ T cells on day 24 after tumor injection in recipients treated as in (a) (n = 10). c YUMM1.5 tumor growth in GF mice undergoing oral gavage with either Altered Schaedler Flora (ASF) or ASF plus bacterial cocktail prior to tumor inoculation (ASF, n = 12; ASF + bacterial cocktail, n = 14). d Quantification of tumor-infiltrating effector (CD44hi) CD4+ and CD8+ T cells and frequencies of IFN-γ+TNF-α+-producing CD4+ and CD8+ T cells on day 21 after tumor injection in mice treated as in (c) (n = 8). e YUMM1.5 tumor growth in GF mice undergoing oral gavage with ASF or ASF plus B. rodentium prior to tumor inoculation (n = 15). f Quantification of tumor-infiltrating effector (CD44hi) CD4+ and CD8+ T cells and frequencies of IFN-γ+TNF-α+-producing CD8+ T cells on day 24 after tumor injection in mice treated as in (e) (n = 8). Data are one experiment ≥8 mice per group.Graphs are the mean ± s.e.m. *P < 0.05, **P < 0.005, ****P < 0.0001 by two-way ANOVA with Tukey’s or Sidak’s correction for multiple comparisons (a, c, e) or two-tailed t test or Mann–Whitney U test (b, d, f)
Fig. 4 Oral administration of select bacterial strains enriched in Rnf5−/− mice to gnotobiotic mice enhances antitumor immune response. a YUMM1.5 tumor growth in germ-free (GF) mice undergoing oral gavage with WT or Rnf5−/− cecal contents 2 weeks prior to tumor implantation (n = 10). b Quantification of tumor-infiltrating CD45+ cells, effector (CD44hi) CD4+ and CD8+ T cells, total CD45+ cells, and frequencies of IFN-γ+TNF-α+-producing CD4+ and CD8+ T cells on day 24 after tumor injection in recipients treated as in (a) (n = 10). c YUMM1.5 tumor growth in GF mice undergoing oral gavage with either Altered Schaedler Flora (ASF) or ASF plus bacterial cocktail prior to tumor inoculation (ASF, n = 12; ASF + bacterial cocktail, n = 14). d Quantification of tumor-infiltrating effector (CD44hi) CD4+ and CD8+ T cells and frequencies of IFN-γ+TNF-α+-producing CD4+ and CD8+ T cells on day 21 after tumor injection in mice treated as in (c) (n = 8). e YUMM1.5 tumor growth in GF mice undergoing oral gavage with ASF or ASF plus B. rodentium prior to tumor inoculation (n = 15). f Quantification of tumor-infiltrating effector (CD44hi) CD4+ and CD8+ T cells and frequencies of IFN-γ+TNF-α+-producing CD8+ T cells on day 24 after tumor injection in mice treated as in (e) (n = 8). Data are one experiment ≥8 mice per group.Graphs are the mean ± s.e.m. *P < 0.05, **P < 0.005, ****P < 0.0001 by two-way ANOVA with Tukey’s or Sidak’s correction for multiple comparisons (a, c, e) or two-tailed t test or Mann–Whitney U test (b, d, f)CC BY · PubMed Central
Fig. 5 IEC of Rnf5−/− mice activate immune response and change anti-microbial peptide (AMP) expression. a Villi length and crypt depth calculated from H&E-stained sections of intestines from WT or Rnf5−/− mice (WT, n = 30; Rnf5−/−, n = 32). b qRT-PCR analysis of AMPs mRNA levels in IECs from small intestine of naive WT or Rnf5−/− mice (n = 6). c Representative images (left) and quantification (right) of cleaved caspase-3 immunostained small intestine organoids from tumor-bearing WT or Rnf5−/− mice (n = 3). Scale bar = 100μm. Graph shows percentage of cleaved caspase-3 + cells per immunostained organoid (n = 12 fields). d Intracellular IFN-γ and TNF-α staining of p14 CD8+ T cells incubated for 72 h with 2 μg/ml GP33 peptide recognized by the TCR of P14 and bone marrow-derived dendritic cells (BMDCs) that were incubated with medium alone (no stimulation) or with conditioned medium (CM) from shControl or shRNF5 MODE-K cells. e Representative images (left) and quantification (right) of CD11c+ cell immunostaining in the small intestine of WT or Rnf5−/− mice on day 24 after injection of YUMM1.5 cells. Scale bar = 50μm (n = 4). f Frequencies of total DCs and pDCs in Peyer’s patches from WT and Rnf5−/− mice on day 10 after YUMM1.5 cell injection (n = 6). g 10 days after tumor injection, DCs from GALT, dLN, and ndLN were isolated, pooled per group (n = 10 mice/group), and were incubated with OT-1 CD8+ T cells stimulated with 2 μg/ml OVA peptide (SINFEKL). Intracellular IFN-γ and TNF-α of OT-1 CD8+ T cells were detected. Data are representative of three independent experiments (b, d) and two independent experiments (a, c, e, f, g) ≥3 mice per group. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-tailed t test or Mann–Whitney U test (a, b, c, e, f) or one-way ANOVA with Tukey’s (d) correction for multiple comparisons
Fig. 5 IEC of Rnf5−/− mice activate immune response and change anti-microbial peptide (AMP) expression. a Villi length and crypt depth calculated from H&E-stained sections of intestines from WT or Rnf5−/− mice (WT, n = 30; Rnf5−/−, n = 32). b qRT-PCR analysis of AMPs mRNA levels in IECs from small intestine of naive WT or Rnf5−/− mice (n = 6). c Representative images (left) and quantification (right) of cleaved caspase-3 immunostained small intestine organoids from tumor-bearing WT or Rnf5−/− mice (n = 3). Scale bar = 100μm. Graph shows percentage of cleaved caspase-3 + cells per immunostained organoid (n = 12 fields). d Intracellular IFN-γ and TNF-α staining of p14 CD8+ T cells incubated for 72 h with 2 μg/ml GP33 peptide recognized by the TCR of P14 and bone marrow-derived dendritic cells (BMDCs) that were incubated with medium alone (no stimulation) or with conditioned medium (CM) from shControl or shRNF5 MODE-K cells. e Representative images (left) and quantification (right) of CD11c+ cell immunostaining in the small intestine of WT or Rnf5−/− mice on day 24 after injection of YUMM1.5 cells. Scale bar = 50μm (n = 4). f Frequencies of total DCs and pDCs in Peyer’s patches from WT and Rnf5−/− mice on day 10 after YUMM1.5 cell injection (n = 6). g 10 days after tumor injection, DCs from GALT, dLN, and ndLN were isolated, pooled per group (n = 10 mice/group), and were incubated with OT-1 CD8+ T cells stimulated with 2 μg/ml OVA peptide (SINFEKL). Intracellular IFN-γ and TNF-α of OT-1 CD8+ T cells were detected. Data are representative of three independent experiments (b, d) and two independent experiments (a, c, e, f, g) ≥3 mice per group. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-tailed t test or Mann–Whitney U test (a, b, c, e, f) or one-way ANOVA with Tukey’s (d) correction for multiple comparisonsCC BY · PubMed Central
Fig. 6 IEC of Rnf5−/− mice activate immune responses and changes AMPs expression by IRE1α/sXBP1 signaling. a Western blot analysis of the indicated proteins in lysates of MODE-K-shCon and MODE-K-shRNF5 cells treated with thapsigargin (TG, 1 μM) for indicated time. b qRT-PCR analysis of mRNA levels of sXBP1, XBP1 and target genes in small intestine-derived IECs from naive WT or Rnf5−/− mice (n = 4). c Representative micrographs of immunohistochemical (IHC) staining of BiP in the jejunum, ileum, and colon of YUMM1.5 tumor-bearing WT or Rnf5−/− mice (scale bar = 25 μm). Lower graphs show quantification of IHC staining (n = 12 fields per group). Staining was scored semi-quantitatively based on staining intensity (0, 1, 2, or 3) multiplied by the percentage of positively stained cells (0–100), to give a maximum IHC score of 300. d Quantification of BiP and CHOP IHC staining in ileum sections from WT and Rnf5−/− mice co-housed for 4 weeks prior to tumor inoculation (n = 12). e qRT-PCR analysis of sXBP1 mRNA levels in MODE-K-shCon and MODE-K-shRNF5 cells treated with the indicated concentration of MKC-4485 for 24 h (n = 3). f MFI of MHC class I and II on bone marrow-derived dendritic cells (BMDCs) incubated with media alone (no stimulation), conditioned media (CM) from shControl or shRNF5 MODE-K cells treated with MKC-4485 (n = 4). g qRT-PCR analysis of Defa1 mRNA levels in MODE-K-shCon and MODE-K-shRNF5 cells (n = 3). h qRT-PCR analysis of AMPs mRNA levels in IECs in MODE-K-shCon and MODE-K-shXBP1 cells (n = 3). i, qRT-PCR analysis of Defa1 mRNA levels in MODE-K cells treated with 2 μM MKC-4485 for 24 h (n = 3). Data are representative of three independent experiments (b, e–i) and two independent experiments (a, c, d) ≥3 mice per group. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-tailed t test or Mann–Whitney U test (b, c, g–i) or one-way ANOVA with Tukey’s correction for multiple comparisons (d–f)
Fig. 6 IEC of Rnf5−/− mice activate immune responses and changes AMPs expression by IRE1α/sXBP1 signaling. a Western blot analysis of the indicated proteins in lysates of MODE-K-shCon and MODE-K-shRNF5 cells treated with thapsigargin (TG, 1 μM) for indicated time. b qRT-PCR analysis of mRNA levels of sXBP1, XBP1 and target genes in small intestine-derived IECs from naive WT or Rnf5−/− mice (n = 4). c Representative micrographs of immunohistochemical (IHC) staining of BiP in the jejunum, ileum, and colon of YUMM1.5 tumor-bearing WT or Rnf5−/− mice (scale bar = 25 μm). Lower graphs show quantification of IHC staining (n = 12 fields per group). Staining was scored semi-quantitatively based on staining intensity (0, 1, 2, or 3) multiplied by the percentage of positively stained cells (0–100), to give a maximum IHC score of 300. d Quantification of BiP and CHOP IHC staining in ileum sections from WT and Rnf5−/− mice co-housed for 4 weeks prior to tumor inoculation (n = 12). e qRT-PCR analysis of sXBP1 mRNA levels in MODE-K-shCon and MODE-K-shRNF5 cells treated with the indicated concentration of MKC-4485 for 24 h (n = 3). f MFI of MHC class I and II on bone marrow-derived dendritic cells (BMDCs) incubated with media alone (no stimulation), conditioned media (CM) from shControl or shRNF5 MODE-K cells treated with MKC-4485 (n = 4). g qRT-PCR analysis of Defa1 mRNA levels in MODE-K-shCon and MODE-K-shRNF5 cells (n = 3). h qRT-PCR analysis of AMPs mRNA levels in IECs in MODE-K-shCon and MODE-K-shXBP1 cells (n = 3). i, qRT-PCR analysis of Defa1 mRNA levels in MODE-K cells treated with 2 μM MKC-4485 for 24 h (n = 3). Data are representative of three independent experiments (b, e–i) and two independent experiments (a, c, d) ≥3 mice per group. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-tailed t test or Mann–Whitney U test (b, c, g–i) or one-way ANOVA with Tukey’s correction for multiple comparisons (d–f)CC BY · PubMed Central
Fig. 7 Altered UPR in melanoma responders of anti-CTLA-4 immune therapy. a Analysis of ER stress markers genes in non-responders (NR) (n = 16) and responders (R) (n = 14) to immune checkpoint therapy in melanoma samples from MGH/DFCC (USA). b Analysis of ER stress markers genes in NR (n = 16) and R (n = 9) to anti-CTLA-4 immunotherapy in melanoma samples from Zurich Hospital (Switzerland). c Kaplan–Meier curves for progression-free survival probability in melanoma patients demonstrating low (n = 15 patients) versus high sXBP1(n = 14 patients) in tumor specimens obtained before immune checkpoint therapy at MGH/DFCC. d Kaplan–Meier estimates of progression-free survival probability in melanoma patients demonstrating low (n = 14 patients) versus high ATF4 (n = 16 patients) in tumor specimens obtained before immune checkpoint therapy in melanoma samples at MGH/DFCC. e Representative micrographs of IHC staining of BiP after anti-PD-1 immunotherapy in melanoma samples obtained at Rambam Health Care Center (Israel) (scale bar = 25 μm). f IHC score of BiP staining in NR (n = 10) and R (n = 11) to anti-PD-1 immunotherapy in melanoma samples from Rambam Health Care Center (Israel). g, h Kaplan–Meier estimates of (g) overall survival and (h) disease-free survival probability in melanoma patients demonstrating low (<25%, n = 12 patients) versus high melanoma cell expression of BiP (>25%, n = 9 patients) in tumor biospecimens obtained before initiation of systemic anti-PD-1 antibody treatment in melanoma samples from Rambam Health Care Center (Israel). i IHC staining of BiP in melanoma samples from select patients prior to, on and after immunotherapy treatment from MGH/DFCC (USA). Scale bar = 50 μm. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-tailed t-test or Mann–Whitney U test (a, b, f) or log-rank test (c, d, g, h)
Fig. 7 Altered UPR in melanoma responders of anti-CTLA-4 immune therapy. a Analysis of ER stress markers genes in non-responders (NR) (n = 16) and responders (R) (n = 14) to immune checkpoint therapy in melanoma samples from MGH/DFCC (USA). b Analysis of ER stress markers genes in NR (n = 16) and R (n = 9) to anti-CTLA-4 immunotherapy in melanoma samples from Zurich Hospital (Switzerland). c Kaplan–Meier curves for progression-free survival probability in melanoma patients demonstrating low (n = 15 patients) versus high sXBP1(n = 14 patients) in tumor specimens obtained before immune checkpoint therapy at MGH/DFCC. d Kaplan–Meier estimates of progression-free survival probability in melanoma patients demonstrating low (n = 14 patients) versus high ATF4 (n = 16 patients) in tumor specimens obtained before immune checkpoint therapy in melanoma samples at MGH/DFCC. e Representative micrographs of IHC staining of BiP after anti-PD-1 immunotherapy in melanoma samples obtained at Rambam Health Care Center (Israel) (scale bar = 25 μm). f IHC score of BiP staining in NR (n = 10) and R (n = 11) to anti-PD-1 immunotherapy in melanoma samples from Rambam Health Care Center (Israel). g, h Kaplan–Meier estimates of (g) overall survival and (h) disease-free survival probability in melanoma patients demonstrating low (<25%, n = 12 patients) versus high melanoma cell expression of BiP (>25%, n = 9 patients) in tumor biospecimens obtained before initiation of systemic anti-PD-1 antibody treatment in melanoma samples from Rambam Health Care Center (Israel). i IHC staining of BiP in melanoma samples from select patients prior to, on and after immunotherapy treatment from MGH/DFCC (USA). Scale bar = 50 μm. Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-tailed t-test or Mann–Whitney U test (a, b, f) or log-rank test (c, d, g, h)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 230

Metadata

Authors
Li, Y., Tinoco, R., Elmén, L., Segota, I., Xian, Y., Fujita, Y., Sahu, A., Zarecki, R., Marie, K., Feng, Y., Khateb, A., Frederick, D. T., Ashkenazi, S. K., Kim, H., Perez, E. G., Day, C.-P., Segura Muñoz, R. S., Schmaltz, R., Yooseph, S., Tam, M. A., Zhang, T., Avitan-Hersh, E., Tzur, L., Roizman, S., Boyango, I., Bar-Sela, G., Orian, A., Kaufman, R. J., Bosenberg, M., Goding, C. R., Baaten, B., Levesque, M. P., Dummer, R., Brown, K., Merlino, G., Ruppin, E., Flaherty, K., Ramer-Tait, A., Long, T., Peterson, S. N., Bradley, L. M., & Ronai, Z. A.
Affiliations
  • Sanford Burnham Prebys Medical Discovery Institute (US)
  • University of Nebraska–Lincoln (US)
  • University of Maryland, College Park (US)
  • Tel Aviv University (IL)
  • National Institutes of Health (US)
  • Technion – Israel Institute of Technology (IL)
  • Harvard University (US)
  • University of Central Florida (US)
  • BioLegend (United States) (US)
  • National Cancer Institute (US)
  • Yale University (US)
  • University of Oxford (GB)
  • University of Zurich (CH)
Corresponding author
Ronai, Ze’ev A.
Venue
Nature Communications
Published
2019-04-02
Volume
10
Issue
1
Pages
1492-1492
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2930205604
Cited by
212
References
50
Citations by year
2026: 13 · 2025: 23 · 2024: 37 · 2023: 35 · 2022: 41 · 2021: 36 · 2020: 21 · 2019: 6
FWCI
8.60
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • Lincoln (University of Nebraska) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Research Explorer (The University of Manchester) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Melanoma Research Alliance (509524)
  • National Institutes of Health (CA030199)
  • Engineering and Physical Sciences Research Council (EP/K040375/1)
  • National Cancer Institute (R35CA197465, DK103185, CA198103, CA 030199, R01CA198103, P01CA128814, R01CA216187, P30CA030199)
  • National Institute of Allergy and Infectious Diseases (R01AI106895)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK113171, R01DK103185)
  • Congressionally Directed Medical Research Programs (CA150892)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
gut microbiota, antitumor immunity, melanoma, RNF5, ubiquitin ligase, unfolded protein response, inflammasome, dendritic cells, antimicrobial peptides, immune checkpoint therapy, germ-free mice, cohousing
MeSH terms
Gastrointestinal Microbiome, Animals, Bacteria, Humans, Intestines, Melanoma, Membrane Proteins, Mice, Inbred C57BL, Mice, Knockout, Antimicrobial Cationic Peptides, Ubiquitin-Protein Ligases, Cell Proliferation, Mice, Unfolded Protein Response

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice. https://app.cochat.ai/papers/10.1038/s41467-019-09525-y
The paper
Li, Y., Tinoco, R., Elmén, L., Segota, I., Xian, Y., Fujita, Y., Sahu, A., Zarecki, R., Marie, K., Feng, Y., Khateb, A., Frederick, D. T., Ashkenazi, S. K., Kim, H., Perez, E. G., Day, C.-P., Segura Muñoz, R. S., Schmaltz, R., Yooseph, S., . . . Ronai, Z. A. (2019). Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice. Nature Communications. https://doi.org/10.1038/s41467-019-09525-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.